Apogee Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Apogee Therapeutics, Inc. (APGE) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $57.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-02
- Apogee Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $57.10M, a 24.40% increase from fiscal 2024.
- Apogee Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $45.90M, a 95.32% increase from fiscal 2023.
- Apogee Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $23.50M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 11 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|
| 2025-12-31 | $57.10M 10-K · filed 2026-03-02 | |
| 2024-12-31 | $45.90M 10-K · filed 2026-03-02 | |
| 2023-12-31 | $23.50M 10-K · filed 2025-03-03 | |
| 2022-12-31 | $6.70M 10-K · filed 2024-03-05 |